Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report

Immunotherapy-associated autoimmune hemolytic anemia

(2017) Uqba Khan et al.   Journal for ImmunoTherapy of Cancer

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma

(2016) Benjamin Y. Kong et al.   MELANOMA RESEARCH

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

(2015) Ninh M. La-Beck et al.   PHARMACOTHERAPY

The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study

(2014) A. Maccio et al.   HAEMATOLOGICA

PD-1 is a novel regulator of human B-cell activation

(2012) Marie-Laure Thibult et al.   INTERNATIONAL IMMUNOLOGY